2023
Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis
John B, Dang Y, Kaplan D, Jou J, Taddei T, Spector S, Martin P, Bastaich D, Chao H, Dahman B. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis. Clinical Gastroenterology And Hepatology 2023, 22: 778-788.e7. PMID: 38061410, PMCID: PMC10960676, DOI: 10.1016/j.cgh.2023.11.020.Peer-Reviewed Original ResearchSustained virological responseLiver stiffness measurementHepatitis C virusHepatocellular carcinomaHCV cirrhosisDiabetes mellitusAnnual riskChronic hepatitis C virusPortal hypertension-related complicationsRate of HCCRisk of HCCHypertension-related complicationsRetrospective cohort studyVeterans Health AdministrationStiffness measurementHCV eradicationVirological responseCohort studyC virusHCC riskLower riskCirrhosisCutoff levelHealth AdministrationAbstractText
2022
Oral Cyanobacteria and hepatocellular carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and hepatocellular carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0804-a.2021. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2019
Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study
Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLOS ONE 2019, 14: e0221614. PMID: 31449554, PMCID: PMC6709904, DOI: 10.1371/journal.pone.0221614.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness ratioHCC treatmentLife expectancyDifferent surveillance intervalsDecision-analytic Markov modelHepatitis C virusCause of deathAspirational scenarioCurrent HCVHCC surveillanceHCC incidenceHepatitis CSurveillance intervalsC virusCancer surveillanceVeteran outcomesLower incidenceStudy groupHCVTreatment useCirrhosisEpidemiologic studiesPatientsCompliance rateRegional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
2017
Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES
Butt AA, Ren Y, Re V, Taddei T, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clinical Infectious Diseases 2017, 65: 64-72. PMID: 28369305, DOI: 10.1093/cid/cix224.Peer-Reviewed Original ResearchConceptsHCV-positive personsHepatic decompensationFIB-4 scoreHuman immunodeficiency virusFIB-4Hepatocellular carcinomaCause mortalityLower riskHCV diagnosisClinical outcomesHepatitis C virus-infected personsHepatitis B surface antigenCohort of HCVVirus-infected personsB surface antigenHepatitis C virusChild-TurcotteChild-PughEarly complicationsMELD scoreImmunodeficiency virusC virusIncidence ratePositive personsTreatment decisions